Navigation Links
Planning for bacteria in cancer patients may help hospitals fight infections
Date:1/23/2013

What cancerous conditions lead to what kinds of bacterial infections? If doctors knew, they could predict which patients would likely benefit from pre-treatment with certain kinds of antibiotics. A University of Colorado Cancer Center study published in this month's issue of the International Journal of Infectious Diseases shows the answer: E. coli and Klebsiella pneumoniae are especially prevalent in patients with lung and GI cancers, more so for Klebsiella if these patients have been treated previously with aminopenicillins.

"These are really dangerous infections. You think about Klebsiella it can develop resistance really quickly. And these patients have generally been in and out of hospitals. If you can't treat the infection early, it can quickly become a serious and life threatening condition," says Andrs Felipe Henao-Martnez, MD, clinical fellow in infectious diseases at the CU Cancer Center and University of Colorado Hospital.

His study looked at 462 patients with bacterial blood stream infections who were admitted to hospitals for treatment. Of these patients, 203 had cancer and 259 did not, allowing Henao-Martnez and colleagues to explore the clinical and microbiological differences between these populations. Interestingly, Henao-Martnez could show that most infections existing in cancer patients were acquired in hospital settings and not in the community, while non-cancer patients typically had community-acquired infections.

"Normally every hospital has a spreadsheet, an antibiogram, listing the bacteria and their rate of antibiotic resistance they've found in their patient population. But if you can predict ahead of time what bacteria you're likely to encounter, you can prescribe more targeted antibiotic therapy before infections create complications," Henao-Martnez says.

For example, previous treatment with aminopenicillins, like amoxicillin, and the presence of cancer seemed to significantly increase the likelihood of Klebsiella infection .

"Klebsiella pneumoniae is largely resistant to amoxicillin with the immune system compromised by the cancer and by chemotherapy, and with other bacteria largely wiped away by the amoxicillin class of antibiotics it appears that Klebsiella is left to flourish with little competition in patients with cancer" Henao-Martnez says.

The group recently submitted a paper detailing genetic differences in outcomes in this population of bacterially infected patients admitted for treatment.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Bloomberg School receives $28 million for family planning advocacy
2. Career Planning for Research Bioscientists
3. Virtual plant planning, retrofitting and maintenance
4. SeaSketch, the next generation of UCSBs MarineMap program, will aid marine spatial planning
5. NOAA science supports New Yorks offshore energy planning
6. Study: Odd biochemistry yields lethal bacterial protein
7. Antibacterial agent used in common soaps found in increasing amounts in freshwater lakes
8. Stopping smoking reduces risk of bacterial pneumonia in people with HIV
9. Designer bacteria may lead to better vaccines
10. MBL scientists find bipolar marine bacteria, refuting everything is everywhere idea
11. The saline hiding places for bacteria in Río Tinto could be like those on Mars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2017)... 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against ... Used combined in one project, ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that ... uncover insights to support its reporting, help direct future campaigns, and ... youth charity will be using Brandwatch Analytics social listening and analytics ... of the topics and issues that are a priority for its ... "Until recently ...
(Date:3/2/2017)... March 2, 2017 Summary This ... understand Merck KGaA and its partnering interests and activities ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... NEWARK, Del. , March 29, 2017 /PRNewswire/ ... company, and W. L. Gore & Associates, ... a collaborative research agreement whereby the two companies will ... device technologies that provide protection from immune rejection. ... been developing innovative stem cell-derived cell replacement therapies with ...
(Date:3/29/2017)... TORONTO , March 29, 2017 /PRNewswire/ -  GeneNews Limited ... of BreastSentry™ , a new risk stratification test for ... reference lab, Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based ... five-year and lifetime risk for developing breast cancer.   ... BreastSentry measures ...
(Date:3/29/2017)... , March 29, 2017 The Global Microfluidic ... report is a specialized and comprehensive study on the existing state ... America , Europe and ... Middle East and Africa . ... Browse 172 Tables and ...
(Date:3/28/2017)... ... 2017 , ... NetDimensions announced today that Scandinavian Health Limited ... management for consistent implementation of standards and regulatory requirements across SHL companies worldwide. ... improve and streamline their training and employee development programs, which are critical to ...
Breaking Biology Technology: